ACCUTANE Drug Patent Profile

Which patents cover Accutane, and when can generic versions of Accutane launch?

Accutane is a drug marketed by Hoffmann La Roche and is included in one NDA.

The generic ingredient in ACCUTANE is isotretinoin. There are thirteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Accutane

A generic version of ACCUTANE was approved as isotretinoin by AMNEAL PHARMS NY on September 29^th, 2017.

Summary for ACCUTANE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ACCUTANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-002	May 7, 1982		DISCN	Yes	No
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-004	Mar 28, 1983		DISCN	Yes	No
Hoffmann La Roche	ACCUTANE	isotretinoin	CAPSULE;ORAL	018662-003	May 7, 1982		DISCN	Yes	No

International Patents for ACCUTANE

See the table below for patents covering ACCUTANE around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	188578
Netherlands	7108586
Latvia	5015	1-(1,3-dioksolan-2-ilmetil)-1H-imidazola vai-1H-1,2,4-triazola atvasinajumu vai to skabju-aditivo salu iegusanas metode maisijuma vai atsevisku
Australia	521329
Ireland	35391	PHARMACEUTICAL PREPARATIONS AND A PROCESS FOR THEIR MANUFACTURE

Summary:
Accutane (isotretinoin) is a systemic retinoid used primarily for severe acne treatment. Its patent expiration, regulatory landscape, and litigation history influence its market potential. Investment in isotretinoin relies on assessing existing patents, regulatory pathways, and competitive dynamics. Fundamentals analysis indicates a mature market with limited growth prospects, but legal and patent challenges could create new value opportunities.

---

What Is the Current Market and Patent Status of Accutane?

Accutane was originally developed and marketed by Hoffmann-La Roche. Its primary patent expired around 2002, with market dominance shifting toward generic versions. Roche's exclusivity ended years earlier, and multiple manufacturers now produce isotretinoin generics.

• Patent Timeline:

Last updated: February 6, 2026

• Original patent expiration: ~2002.
• Patent challenges and litigation occurred in the early 2000s, but no new patents significantly extended exclusivity.
• The active pharmaceutical ingredient (API) patent for isotretinoin is no longer in force.

Regulatory Status:

• Approved by the FDA for severe recalcitrant nodular acne.
• Replaced in many markets by generic versions.
• No recent additional approvals or reformulations under patent protection.

Market Dynamics:

• The global isotretinoin market was valued at approximately $400 million in 2022.[1]
• Generic competition has driven prices down, reducing revenue potential for brand-name formulations.
• Use is limited by strict regulation due to teratogenicity risks, affecting overall market size.

---

What Are the Key Investment and Development Opportunities?

1. Patent and Litigation Strategies

   • No current patent protections for formulations beyond manufacturing patents.
   • Some companies explore new formulations (e.g., extended-release) to create patentable IP.
   • Litigation history indicates aggressive patent challenges by generics; legal battles can create temporary market exclusivity.

2. New Formulations and Delivery Platforms

   • Innovations like liposomal or nanoformulations could extend patent protection.
   • Extended-release formulations aim to improve tolerability and compliance, potentially commanding premium pricing.

3. Regulatory and Reimbursement Environment

   • Strict regulation due to teratogenic effects limits sales channels.
   • Some markets enforce risk management programs that restrict supply, impacting sales.

4. Potential for Combination Therapies

   • Combining isotretinoin with other acne treatments may emerge in clinical trials, creating new therapeutic niches.

---

What Are the Fundamental Risks?

• Market Saturation: The market is saturated with low-cost generics, limiting revenue growth.
• Regulatory Constraints: Strict controls on distribution due to teratogenicity impair market size and accessibility.
• Legal and Patent Challenges: Ongoing patent litigations and potential patent expirations threaten market exclusivity.
• Off-Label Use: While off-label use does occur, it likely does not significantly influence revenues due to regulatory restrictions.
• Reformularization Risks: While reformulations might extend IP, regulatory hurdles and clinical trials increase development costs and timelines.

---

What Are the Financial and R&D Trends?

• Market Revenue: Approximate $400 million globally in 2022, with a decline from peak historical revenues due to increased generic usage.
• R&D Investment: Limited R&D for new formulations; focus shifts to new delivery systems or combination therapies.
• Pricing Trends: Prices have fallen sharply due to generic competition; brand-name formulations are largely replaced.
• Investment Focus: Patents on formulation or delivery methods, licensing opportunities, and litigation strategies.

---

What Is the Competitive Landscape?

Company	Market Share	Key Patent Activities	Notable Initiatives
Hoffman-La Roche (original)	Declined	Expired patents, legal battles	None (exit from market)
Mylan, Teva, Sun Pharma	Majority	Generic manufacturing	Increased market share due to patent challenges
Innovative companies (e.g., Elastagen)	Niche	Novel formulations and delivery	R&D focus, attempts at reformulation

---

Key Takeaways

• Accutane’s primary patents expired over 20 years ago; market is now dominated by generics.
• Revenue potential is constrained by high regulatory barriers and declining drug prices.
• Strategic opportunities exist in formulation innovations, extended-release versions, or combination therapies.
• Ongoing litigation and patent challenges may temporarily extend exclusivity or permit licensing deals.
• Market growth is limited; pharmaceutical companies and investors should evaluate potential gains from R&D or legal strategies within this mature market.

---

FAQs

Q1: Can new formulations of isotretinoin generate patent protections?
Yes. Innovations such as extended-release or liposomal formulations can be patented, but require clinical validation and regulatory approval.

Q2: What impact did patent expirations have on market revenues?
They led to increased generic competition, significantly reducing prices and margins, with a corresponding decline in revenues for brand-name products.

Q3: Are there regulatory barriers to introducing new isotretinoin products?
Yes. Due to teratogenic risks, strict risk management programs exist, especially in the US and EU, significantly limiting distribution channels.

Q4: Is there potential for market growth through licensing or litigation?
Some companies pursue patent litigation or licensing deals to extend market exclusivity temporarily, but fundamental growth opportunities are limited.

Q5: What external factors influence isotretinoin investment decisions?
Regulatory changes, legal challenges, advances in acne treatments, and shifts toward personalized medicine influence opportunities and risks.

---

References

[1] Market Data, IQVIA, 2022.